Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2606 • ACR Convergence 2024
Changes in Long-term GC Use Among Older Adults After New Diagnosis of Late-onset Rheumatoid Arthritis
Jiha Lee¹, Jonathan Martindale¹, Beth Wallace², Namrata Singh³, Una Makris⁴ and Julie Bynum¹, ¹University of Michigan, Ann Arbor, MI, ²Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ³University of Washington, Bellevue, WA, ⁴UT Southwestern Medical Center and Dallas VA, Dallas, TX
Background/Purpose: Older adults with late-onset rheumatoid arthritis (LORA) receive less disease-modifying anti-rheumatic drugs (DMARDs), which is the standard of care. In contrast, long-term glucocorticoid (GC)…
Abstract Number: PP08 • ACR Convergence 2024
Whispers of Resilience: Navigating Life with Rheumatism
Vinchelle Hardison and Vinchelle Hardison, Nationwide Children's Hospital, Columbus, OH
Background/Purpose: “What’s wrong with me mom? Why am I always slow and hurting? Why can’t I play without being in pain like the other kids?”…
Abstract Number: 0036 • ACR Convergence 2024
Deep Topic Modeling Deconvolves Cell States in Spatial Transcriptomic Profiles of Rheumatoid Arthritis Synovial Tissue
Preethi Periyakoil¹, Melanie Smith², Meghana Kshirsagar³, Daniel Ramirez⁴, Edward Dicarlo⁵, Susan Goodman⁶, Laura Donlin² and Christina Leslie⁷, ¹Weill Cornell Medical College, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Microsoft AI for Good, Seattle, ⁴Hospital for Special Surgery, Cartago, Costa Rica, ⁵Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁶Hospital for Special Surgery, New York 10025, NY, ⁷Memorial Sloan Kettering Cancer Center, New York, NY
Background/Purpose: Recent single-cell RNA sequencing (scRNA-seq) studies of the rheumatoid arthritis (RA) synovium have highlighted the heterogeneity of cell states present during active disease. It…
Abstract Number: 0053 • ACR Convergence 2024
Fasting Reduces an IL-17+/IFNg+ T Helper Cell-inducing Gut Pathobiont in Patients with Rheumatoid Arthritis
Márcia Pereira¹, Katja Stuhlträger², Natalie Scherff³, Anika Rajput Khokhar⁴, Sylvio Redanz¹, Hebah Ebid⁵, Bérénice Hansen⁵, Cédric C. Lacny⁵, Ulrike Löschberger², Stefan Bletz⁶, Jochen G. Schneider⁷, Paul Wilmes⁷, Christian S. Kessler⁴, Andreas Michalsen⁴, Alexander Mellmann³ and Martin Kriegel¹, ¹Institute of Musculoskeletal Medicine, University of Münster, Department of Translational Rheumatology and Immunology, Münster, Germany, Münster, Germany, ²Institute of Musculoskeletal Medicine, University of Münster, Department of Translational Rheumatology and Immunology, Münster, Germany, Muenster, Germany, ³Institute of Hygiene, University Hospital Münster, Münster, Germany, Muenster, Germany, ⁴Institute of Social Medicine, Epidemiology and Health Economics, Charité, Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, Berlin, Germany, ⁵4University of Luxembourg, Department of Life Sciences and Medicine (DLSM), 6, Avenue du Swing, L-4367 Belvaux, Luxembourg, Luxemburg, Luxembourg, ⁶Institute of Hygiene, University Hospital Münster, Germany, Muenster, Germany, ⁷University of Luxembourg, Department of Life Sciences and Medicine (DLSM), 6, Avenue du Swing, L-4367 Belvaux, Luxembourg, Luxemburg, Luxembourg
Background/Purpose: The mucosal origins hypothesis suggests rheumatoid arthritis (RA) is triggered at mucosal sites in genetically predisposed hosts1. Animal models support that microbiota‐induced Th17 cells are…
Abstract Number: 0131 • ACR Convergence 2024
Methotrexate and Tumor Necrosis Factor Inhibitors Independently Decrease Neutralizing Antibodies After SARS-CoV-2 Vaccination: Updated Results from the SUCCEED Study
Carol Hitchon¹, Dawn Bowdish², Gilles Boire³, Paul Fortin⁴, Louis Flamand⁵, Vinod Chandran⁶, Roya M Dayam⁷, Anne-Claude Gingras⁸, Catherine Card⁹, Ines Colmegna¹⁰, Maggie Larche², Gil Kaplan¹¹, Luck Lukusa¹², Jennifer Lee¹² and Sasha Bernatsky¹³, and SUCCEED investigative team, ¹University of Manitoba, Winnipeg, MB, Canada, ²McMaster University, Hamilton, ON, Canada, ³Retired, Sherbrooke, QC, Canada, ⁴Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ⁵Centre Hospitalier Universitaire (CHU) de Québec-Université Laval Research Center, Quebec City, ⁶University of Toronto, Toronto, ON, Canada, ⁷Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health, Toronto, ON, Canada, ⁸Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada, ⁹National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada, ¹⁰The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ¹¹University of Calgary, Calgary, AB, Canada, ¹²The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹³Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Given ongoing SARS-CoV-2 circulation, COVID-19 vaccination response in immune-mediated inflammatory disease (IMID) remains a key issue, particularly regarding effects of common immunosuppressives like methotrexate…
Abstract Number: 0207 • ACR Convergence 2024
Investigation of Delays in Cancer Screening in RA
Rebecca Brooks¹, Cassondra Hulshizer², Andrew C. Hanson³, Vanessa Kronzer¹, John Davis¹, Elena Myasoedova¹ and Cynthia Crowson¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Utica, MN, ³Mayo Clinic, Rochester
Background/Purpose: Recent studies have shown that RA patients have increased mortality due to cancer. Despite the increased mortality, few studies have investigated the completion of…
Abstract Number: 0357 • ACR Convergence 2024
Evaluating Meaningful Within-Person Change Thresholds in PROMIS-Fatigue Scores from Three Phase 3 Clinical Trials of Sarilumab for Rheumatoid Arthritis Using Empirical Cumulative Distribution Function (eCDF) Curves
Clifton Bingham¹, Emily Molina², Amy Praestgaard³, Stefano Fiore³ and David Cella⁴, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins, Baltimore, MD, ³Sanofi, Bridgewater, NJ, ⁴Northwestern University, Chicago, IL
Background/Purpose: To evaluate changes over time in fatigue measured by Patient Reported Outcome Measures Information System (PROMIS)-Fatigue scores in rheumatoid arthritis (RA) patients treated with…
Abstract Number: 0457 • ACR Convergence 2024
Metabolic Syndrome, Adipokines, and Response to Advanced Therapies in Rheumatoid Arthritis
Joshua Baker¹, George Reed², Geoffrey Thiele³, Dimitrios Pappas⁴, christina Charles-Schoeman⁵, Monica Guma⁶, Leslie Harrold⁷, Jeffrey Curtis⁸ and Joel Kremer⁹, ¹Department of Medicine, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA, ²University of Massachusetts Chan Medical School, Worcester, MA, ³University of Nebraska Medical Center, Omaha, NE, ⁴CorEvitas, New York, NY, ⁵UCLA Medical Center, Santa Monica, CA, ⁶UCSD, La Jolla, CA, ⁷CorEvitas, Northborough, MA, ⁸University of Alabama at Birmingham, Hoover, AL, ⁹The Corrona Research Foundation, Delray Beach, FL
Background/Purpose: While BMI has been associated with response to therapy in several studies in rheumatoid arthritis (RA), it is not a comprehensive measure of the…
Abstract Number: 0473 • ACR Convergence 2024
Immune Checkpoint–Induced Arthritis: A Comprehensive Single Cohort Descriptive Analysis from Clinical Evaluation to Histology
NATALUCCI Francesco¹, SOKOLOVA Tatiana², NZEUSSEU TOUKAP Adrien³, GALANT Christine⁴, ABOUBAKAR Frank⁵, BAURAIN Jean-François⁶, CORNELIS Frank⁶, BORBATH Yvan⁷, DUREZ Patrick² and MERIC de BELLEFON Laurent², ¹Sapienza University of Roma, Rheumatology, Department of Clinical, Internistic, Anesthesiological and cardiovascular sciences, Roma, Italy, ²Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Belgium, ³Institut de Recherche Expérimentale et Clinique, Cliniques universitaires Saint-Luc, Université catholique de Louvain, St.-Lambrechts-Woluwe, Belgium, ⁴Department of Pathological Anatomy, Cliniques Universitaires Saint-Luc, Brussels, Belgium, ⁵Division of Pneumology, Cliniques Universitaires Saint-Luc, Brussels, Brussels, Belgium, ⁶Medical Oncology Department, Université Catholique de Louvain and Cliniques Universitaires Saint-Luc, Brussels, Belgium, ⁷Department of Hepato-gastroenterology, Cliniques Universitaires St Luc, Brussels, Belgium
Background/Purpose: The increasing use of Immune Check-Point Inhibitors (ICIs) to treat malignancy focused attention on immune-related adverse events (irAEs). ICIs-induced arthritis is the most common…
Abstract Number: 0491 • ACR Convergence 2024
Small Molecule Metabolites, Potential Disease-specific Biomarkers for Predicting Treatment Response in Rheumatoid Arthritis
Jiayi Xu¹, Yi Zhao², Chenxi Zhu³, Yi Liu⁴, Tao Chen¹, Rui Sun³, Huifang Hu⁵, Zhen Zhou¹ and Yan Liu¹, ¹Department of Rheumatology and Immunology, West China Hospital,Sichuan University, Chengdu, Sichuan, China, Cheng du, China (People's Republic), ²Department of Rheumatology and Immunology, West China Hospital,Sichuan University, Chengdu, Sichuan, China, Sichuan, China (People's Republic), ³Department of Rheumatology and Immunology, West China Hospital,Sichuan University, Chengdu, Sichuan, China, chengdu, China (People's Republic), ⁴Department of Rheumatology and Immunology, West China Hospital,Sichuan University, Chengdu, Sichuan, China, chengdu, ⁵Department of Rheumatology and Immunology, West China Hospital,Sichuan University, Chengdu, Sichuan, China, Chengdu, Sichuan, China (People's Republic)
Background/Purpose: Rheumatoid arthritis (RA) is a complex chronic inflammatory condition primarily affecting joints, presenting a challenge in understanding its causes, varied subtypes, diagnostic indicators, and…
Abstract Number: 0507 • ACR Convergence 2024
Neutrophil Activation Markers Can Predict Rheumatoid Arthritis Treatment Response to the Janus Kinase 1/2 Inhibitor Baricitinib
Runa Kuley¹, Bhargavi Duvvuri¹, Sabeeha Hasnain², Ernst Dow³, Alisa Koch⁴, Richard Higgs⁴, Venkatesh Krishnan⁴ and Christian Lood⁵, ¹University of Washington, Seattle, ²Mahindra University, Hyderabad, India, ³Eli Lilly and Co, Indianapolis, IN, ⁴Eli Lilly, Indianapolis, IN, ⁵University of Washington, Seattle, WA
Background/Purpose: Neutrophils play an important role in regulating immune and inflammatory responses in rheumatoid arthritis (RA). We assessed whether baricitinib, a JAK1/JAK2 inhibitor, could reduce…
Abstract Number: 0524 • ACR Convergence 2024
Evaluating Dose Reduction of Biologic Treatments in Rheumatoid Arthritis: Predicting Flares Using Clinical and Molecular Biomarkers
Laura Galindo Domínguez¹, Belen Acasuso², Vanesa Balboa-Barreiro³, Juan Fernández-Tajes², Juan Cañete⁴, Benjamin Fernández-Gutiérrez⁵, Isidoro González-Álvaro⁶, José L Pablos⁷, Carmen Bejerano-Herreria⁸, Maite Silva-Díaz⁹, Franciso javier De-Toro-Santos², Natividad Oreiro¹⁰ and francisco J Blanco¹¹, ¹Instituto de Investigacion Biomedica de A Coruña (INIBIC), A Coruña, Spain, ²Unidad de Investigacion Clinica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas., Investigation, A Coruña, Spain, A Coruña, Spain, ³Unidad de Epidemiología Clínica y Bioeostadística. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC)., A Coruña, Spain, ⁴Hospital Clinic an IDIBAPS, Barcelona, Spain, ⁵3Rheumatology Department, and Health Research Institute (IdISSC), Hospital Clínico San Carlos, Calle del Profesor Martín Lagos, s/n, 28040, Madrid, Spain., Rheumatology, Madrir, Spain, Madrid, Madrid, Spain, ⁶University Hospital La Princesa, Madrid, Madrid, Spain, ⁷Health ministry, Madrid, Madrid, Spain, ⁸Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁹Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, ¹⁰CHUAC, La Coruna, Galicia, Spain, ¹¹INIBIC-University of A Coruña, A Coruña, Spain
Background/Purpose: Reducing the dosage of biologic drugs in patients with rheumatoid arthritis (RA) who have achieved remission is a viable and necessary strategy. To identify…
Abstract Number: 0794 • ACR Convergence 2024
Social Security Work Disability and Its Predictors in Patients with Fibromyalgia: 25 Years of Followup
Shreena Kamlesh Gandhi¹, Sofia Pedro², Brian Walitt³, Winfried Häuser⁴, Robert Katz⁵ and Kaleb Michaud⁶, ¹KU School of Medicine, Wichita, Wichita, KS, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³NIH, Bethesda, MD, ⁴Klinikum Saarbrücken Germany, Munich, Germany, ⁵Rush University Medical Center, Chicago, IL, ⁶University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Disability benefits are crucial for individuals unable to work due to debilitating medical conditions, commonly facilitated through programs like Social Security Disability Insurance (SSD)…
Abstract Number: 0873 • ACR Convergence 2024
Epigenetic Control of Pathogenic CD4 T Cell Polarization During Progression to Rheumatoid Arthritis (RA)
Ziyuan He¹, Pravina Venkatesan¹, Adam Savage¹, Marla Glass¹, Lauren Okada², Upaasana Krishnan², Christy Bennett¹, Nhung Tran², Yudong He², Samir Rachid Zaim¹, Padmapriyadarshini Ravisankar², Jessica Garber², Palak Genge², Kevin Lee², Regina Mettey², Cole Phalen², Sugandhika Khosa², Marie Feser³, Fan Zhang⁴, David Boyle⁵, Kristine Kuhn⁴, Kristen Demoruelle⁶, Cate Speake⁷, Jane Buckner⁸, Ananda Goldrath¹, Thomas Bumol⁹, V. Michael Holers¹⁰, Peter Skene¹, Gary Firestein¹¹, Xiaojun Li¹, Kevin Deane¹², Troy Torgerson¹³ and Mark Gillespie¹, ¹Allen Institute for Immunology, Seattle, WA, ²Allen Institute for Immunology, Seattle, ³Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁴University of Colorado, Aurora, CO, ⁵UCSD, La Jolla, CA, ⁶University of Colorado Anschutz Medical Campus, Golden, CO, ⁷Benaroya Research Institute at Virginia Mason, Seattle, ⁸Benaroya Research Institute, Seattle, WA, ⁹Allen Institute for Immunology, San Diego, CA, ¹⁰University of Colorado, Denver, CO, ¹¹University of California, San Diego, San Diego, CA, ¹²University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ¹³Allen Institute for Immunology, Enumclaw, WA
Background/Purpose: Multiple T cell subsets, including Th1, Th17 cells, and Tfh/Tph, contribute to rheumatoid arthritis (RA) pathology. Clinical trials have shown efficacy of T cell…
Abstract Number: 0939 • ACR Convergence 2024
A Joint-targeting Peptide Enhances the Therapeutic Efficacy of Liposomal Drug Delivery in Experimental Rheumatoid Arthritis
Hemalatha Nanjaiah, Rakeshchandra Meka, Bodhraj Acharya, Shivaprasad Venkatesha and Kamal Moudgil, University of Maryland School of Medicine, Baltimore, Baltimore, MD
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease of synovial joints, and it affects over 1 per cent of the population worldwide. Uncontrolled or…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].